{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T17:43:22Z","timestamp":1790185402662,"version":"4.1.0"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1097\/bor.0000000000000252","type":"journal-article","created":{"date-parts":[[2016,1,16]],"date-time":"2016-01-16T11:10:48Z","timestamp":1452942648000},"page":"140-144","source":"Crossref","is-referenced-by-count":10,"title":["Current advances in therapies for calcium pyrophosphate crystal arthritis"],"prefix":"10.1097","volume":"28","author":[{"given":"Francisca","family":"Sivera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Andr\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliseo","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20210128","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/rheumatology\/kep081","article-title":"An update on the epidemiology of calcium pyrophosphate dihydrate crystal deposition disease.","volume":"48","author":"Richette","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"R2-9-20210128","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/BOR.0b013e3280145289","article-title":"Update in calcium deposition diseases.","volume":"19","author":"Rosenthal","year":"2007","journal-title":"Curr Opin Rheumatol"},{"key":"R3-9-20210128","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.rdc.2014.01.010","article-title":"Nonpharmacologic and pharmacologic management of CPP crystal arthritis and BCP arthropathy and periarticular syndromes.","volume":"40","author":"Rosenthal","year":"2014","journal-title":"Rheum Dis Clin North Am"},{"key":"R4-9-20210128","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1136\/ard.62.6.513","article-title":"UK community prevalence of knee chondrocalcinosis: evidence that correlation with osteoarthritis is through a shared association with osteophyte.","volume":"62","author":"Neame","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"R5-9-20210128","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.rdc.2014.01.011","article-title":"Diagnosis and clinical manifestations of calcium pyrophosphate and basic calcium phosphate crystal deposition diseases.","volume":"40","author":"Ea","year":"2014","journal-title":"Rheum Dis Clin North Am"},{"key":"R6-9-20210128","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.joca.2006.08.012","article-title":"Comparison of characteristics of patients with and without calcium pyrophosphate dihydrate crystal deposition disease who underwent total knee replacement surgery for osteoarthritis.","volume":"15","author":"Viriyavejkul","year":"2007","journal-title":"Osteoarthr Cartilage"},{"key":"R7-9-20210128","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1053\/joca.2002.0861","article-title":"Synovial fluid features and their relations to osteoarthritis severity: new findings from sequential studies.","volume":"11","author":"Nalbant","year":"2003","journal-title":"Osteoarthr Cartilage"},{"key":"R8-9-20210128","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/rheumatology\/29.2.101","article-title":"Synovial fluid calcium pyrophosphate dihydrate crystals and alizarin red positivity: analysis of 3000 samples.","volume":"29","author":"Hamilton","year":"1990","journal-title":"Br J Rheumatol"},{"key":"R9-9-20210128","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jbspin.2012.08.006","article-title":"Prevalence of calcium pyrophosphate and monosodium urate crystals in synovial fluid of patients with previously diagnosed joint diseases.","volume":"80","author":"Oliviero","year":"2013","journal-title":"Joint Bone Spine"},{"key":"R10-9-20210128","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00296-012-2608-9","article-title":"The detection of calcium pyrophosphate crystals in the synovial fluid of patients with rheumatoid arthritis using the cytospin technique: prevalence and clinical correlation.","volume":"34","author":"Theiler","year":"2014","journal-title":"Rheumatol Int"},{"key":"R11-9-20210128","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/ard.2010.139360","article-title":"EULAR recommendations for calcium pyrophosphate deposition. Part II: management.","volume":"70","author":"Zhang","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R12-9-20210128","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.semarthrit.2013.09.006","article-title":"ACTH as a treatment for acute crystal-induced arthritis: update on clinical evidence and mechanisms of action.","volume":"43","author":"Daoussis","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"R13-9-20210128","first-page":"696","article-title":"ACTH revisited: effective treatment for acute crystal induced synovitis in patients with multiple medical problems.","volume":"21","author":"Ritter","year":"1994","journal-title":"J Rheumatol"},{"key":"R14-9-20210128","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jbspin.2013.05.006","article-title":"ACTH as first line treatment for acute calcium pyrophosphate crystal arthritis in 14 hospitalized patients.","volume":"81","author":"Daoussis","year":"2014","journal-title":"Joint Bone Spine"},{"key":"R15-9-20210128","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/art.22389","article-title":"Methotrexate as an alternative therapy for chronic calcium pyrophosphate deposition disease: an exploratory analysis.","volume":"56","author":"Chollet-Janin","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R16-9-20210128","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/RHU.0b013e3182611471","article-title":"Methotrexate is an option for patients with refractory calcium pyrophosphate crystal arthritis.","volume":"18","author":"Andres","year":"2012","journal-title":"J Clin Rheumatol"},{"key":"R17-9-20210128","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1186\/s13075-014-0458-4","article-title":"Methotrexate in chronic-recurrent calcium pyrophosphate deposition disease: no significant effect in a randomized crossover trial.","volume":"16","author":"Finckh","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"R18-9-20210128","first-page":"89","article-title":"Methotrexate: should it still be considered for chronic calcium pyrophosphate crystal disease Arthritis Res T","volume":"17","author":"Pascual","year":"2015","journal-title":"her"},{"key":"R19-9-20210128","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome.","volume":"440","author":"Martinon","year":"2006","journal-title":"Nature"},{"key":"R20-9-20210128","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrrheum.2012.143","article-title":"Uric acid as a danger signal in gout and its comorbidities.","volume":"9","author":"Rock","year":"2013","journal-title":"Nat Rev Rheumatol"},{"key":"R21-9-20210128","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/nature01991","article-title":"Molecular identification of a danger signal that alerts the immune system to dying cells.","volume":"425","author":"Shi","year":"2003","journal-title":"Nature"},{"key":"R22-9-20210128","first-page":"CD009993","article-title":"Interleukin-1 inhibitors for acute gout.","volume":"9","author":"Sivera","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"R23-9-20210128","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jbspin.2011.12.017","article-title":"Efficacy of anakinra in articular chondrocalcinosis: report of three cases.","volume":"79","author":"Couderc","year":"2012","journal-title":"Joint Bone Spine"},{"key":"R24-9-20210128","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jbspin.2012.09.002","article-title":"IL1 blockade in crystal-induced arthritis: impact of disease duration and the inflammatory syndrome. Comments on the article by Couderc M. et al. Efficacy of anakinra in articular chondrocalcinosis.","volume":"80","author":"Verhoeven","year":"2013","journal-title":"Joint Bone Spine"},{"key":"R25-9-20210128","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.jbspin.2012.01.010","article-title":"Efficacy of anakinra for refractory acute calcium pyrophosphate crystal arthritis.","volume":"79","author":"Molto","year":"2012","journal-title":"Joint Bone Spine"},{"key":"R26-9-20210128","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/RHU.0b013e31826149a2","article-title":"Interleukin 1beta blockade improves signs and symptoms of chronic calcium pyrophosphate crystal arthritis resistant to treatment.","volume":"18","author":"Diamantopoulos","year":"2012","journal-title":"J Clin Rheumatol"},{"key":"R27-9-20210128","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jbspin.2012.07.018","article-title":"Efficacy of anakinra in calcium pyrophosphate crystal-induced arthritis: a report of 16 cases and review of the literature.","volume":"80","author":"Ottaviani","year":"2013","journal-title":"Joint Bone Spine"},{"key":"R28-9-20210128","doi-asserted-by":"crossref","first-page":"792173","DOI":"10.1155\/2015\/792173","article-title":"Efficacy of anakinra for various types of crystal-induced arthritis in complex hospitalized patients: a case series and review of the literature.","volume":"2015","author":"Aouba","year":"2015","journal-title":"Mediat Inflamm"},{"key":"R29-9-20210128","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nrrheum.2010.182","article-title":"Pathophysiology of articular chondrocalcinosis: role of ANKH.","volume":"7","author":"Abhishek","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"R30-9-20210128","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1136\/ard.52.6.418","article-title":"Prevalence of articular chondrocalcinosis in elderly subjects in a rural area of Catalonia.","volume":"52","author":"Sanmarti","year":"1993","journal-title":"Ann Rheum Dis"},{"key":"R31-9-20210128","first-page":"1973","article-title":"Does primary or secondary chondrocalcinosis influence long-term survivorship of unicompartmental arthroplasty Clin Orthop Relat R","volume":"470","author":"Hernigou","year":"2012","journal-title":"es"},{"key":"R32-9-20210128","first-page":"1512","article-title":"Does chondrocalcinosis affect Knee Society scores and range of motion after TKA Clin Orthop Relat R","volume":"472","author":"Lee","year":"2014","journal-title":"es"},{"key":"R34-9-20210128","doi-asserted-by":"crossref","first-page":"54","DOI":"10.12968\/hmed.2013.74.1.54","article-title":"A case of mistaken identity: pseudogout in a prosthetic knee.","volume":"74","author":"Swayamprakasam","year":"2013","journal-title":"Br J Hosp Med"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000252","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T23:34:42Z","timestamp":1620948882000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201603000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000252","relation":{},"ISSN":["1040-8711"],"issn-type":[{"value":"1040-8711","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]}}}